Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Approvals Action
Third Hep C treatment registered
BMS's new Hepatitis C therapy Daklinza has been registered on the ARTG, joining Sovaldi and Harvoni as the three await PBS listing.
Special Report
Image problems continue to beset pharma
A spate of mainstream media coverage from tax to medicine prices to trade agreements continues to portray Aussie pharma in a negative light - does the industry have only itself to blame?
Special Report
Big changes proposed at TGA
A wide range of changes have been mooted for the regulator which could speed up approval of medicines and see more information shared post- market, with other regulators and across reimbursement applications.
Pipeline Monitor
BMS ahead in new cancer class
BMS has won the race for new cancer class PD-1 in Europe, where Gardasil 9 has also been approved while Eisai has won a new epileptic indication for Fycompa in the US.
Working Life
Awards season: deadlines near for major gongs
The pharmaceutical industry has several awards every year and deadlines are nearing for some big ones; others will give you a bit more time.